Compare American Electric Power Company Inc (AEP) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs Mesoblast Limited — how do they compare? American Electric Power Company Inc trades at $123.61 (market cap $66.87B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: American Electric Power Company Inc is far larger — about 31× Mesoblast Limited's market cap, and American Electric Power Company Inc pays a 3.09% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| AEP | MESO | |
|---|---|---|
Market Cap | $66.87B | $2.16B |
Sector | Utilities | Technology |
52-Week High | $138.69 | $20.96 |
52-Week Low | $106.44 | $12.88 |
Enterprise Value | $119.77B | $2.17B |
Dividend Yield | 3.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Electric Power (AEP) trades at $125.73, up 0.38% on the day, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 per share versus $1.48 expected, though the company raised full-year 2026 operating EPS guidance to $6.25–$6.55, reflecting confidence in AI-driven power demand growth. Fundamentals show robust revenue growth to $21.88B in 2025 and a net income margin of 13.78%, supported by a $78 billion capital plan.
The outlook remains positive due to contracted load growth and infrastructure investments, but risks include execution of large capital expenditures and interest rate sensitivity. With a consensus price target of $140.89 and no sell ratings, Wall Street sentiment is bullish, though technical indicators suggest near-term caution amid bearish moving averages.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
